HISUN(SH:600267) Zheng Quan Zhi Xing·2025-08-25 17:05Core Points - The articles outline the regulations and governance structure of Zhejiang Hisun Pharmaceutical Co., Ltd, emphasizing the protection of the rights of shareholders, employees, and creditors [1][3][4] - The company is established as a publicly listed joint-stock company with a registered capital of RMB 1,198.848196 million [2][7] - The company aims to be a leading pharmaceutical enterprise focusing on research and innovation, adhering to high production standards [5][6] Group 1: General Provisions - The company is established under the Company Law and other relevant regulations, with its legal representative being the chairman elected by the board [1][2] - The company has a permanent existence as a publicly listed joint-stock company [2] - The articles serve as a legally binding document governing the relationships and rights among the company, shareholders, and management [3][4] Group 2: Business Objectives and Scope - The company's business objective is to provide high-quality pharmaceutical products and health solutions globally, driven by research and innovation [5] - The business scope includes drug production, pharmaceutical wholesale, and various related activities, subject to legal approvals [5][6] Group 3: Shares - The company issues shares in the form of stocks, ensuring equal rights for all shares of the same category [7][8] - The total number of issued shares is 1,198,481,196, all of which are ordinary shares [7][8] - The company can provide financial assistance for acquiring its shares under specific conditions approved by the board [8][9] Group 4: Shareholder Rights and Meetings - Shareholders have rights to dividends, voting, and participation in company decisions, with equal rights for shares of the same category [14][15] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [48][49] - Shareholder proposals must be submitted within a specified timeframe before meetings, ensuring transparency and participation [58][59]